Fig. 7.
Therapeutic treatment of chronic EAE with mtROS inhibitor lessens clinical severity and dampens CNS autoimmune inflammation. (A) C57BL/6 mice with chronic EAE were i.p. injected from 9 dpi (arrow) to 31 dpi with vehicle or SKQ1 (n = 8–9/group) and monitored for clinical signs of disease (mean ± SEM). Data represent one of two independent experiments that yielded similar results. (B) Motor function was evaluated by the wire-hang test at 31 dpi. (C) Proliferation and cytokine production of splenocytes isolated from EAE mice (n = 5/group) at 31 dpi, pooled, and restimulated with MOG35–55. Data represent mean ± SEM of duplicate wells. (D) Neuropathological analysis of spinal cord sections from EAE mice (31 dpi) stained with H&E and antimyelin basic protein (MBP) (n = 3–4/group). (Scale bars: 500 μm and 100 μm.) *Immune cell infiltration and demyelinated areas. Data in plots are mean ± SEM. *P < 0.05; § or **P < 0.01; # or ***P < 0.001; ****P < 0.0001. P values were determined by the Mann–Whitney U test in A and B, the two-tailed unpaired t test with Holm–Sidak correction in C, and the two-tailed unpaired t test in D.